The lack of a meaningful therapeutic effect in this moderate PD lesion model could mean that higher levels of drug in the CNS are needed to achieve enough activity to combat more severe insults, or alternatively one could explore the different receptor specificity (PAC1 vs. VPAC1/2) to improve therapeutic potency. This evidence concerns the gene VIPR1 and Parkinson disease.